BIOMARCADORES PARA DIAGNÓSTICO DE DEMENCIA

Volver

Resultados 67 resultados LastUpdate Última actualización 18/02/2018 [16:03:00] pdf PDF




Solicitudes publicadas en los últimos 60 días / Applications published in the last 60 days



Página1 de 3 nextPage   Mostrar por página


METHOD OF DIAGNOSIS, PROGNOSIS OR TREATMENT OF NEURODEGENERATIVE DISEASES

NºPublicación: US2018045740A1 15/02/2018

Solicitante:
CENTRE NAT RECH SCIENT [FR]
UNIV PARIS VAL DE MARNE [FR]
UNIV PIERRE ET MARIE CURIE PARIS 6 [FR]
ICM INST DU CERVEAU ET DE LA MOELLE EPINIERE [FR]
OTR3 [FR]
ASSIST PUBLIQUE HOPITAUX DE PARIS [FR]

Resumen de: US2018045740A1

Methods for the diagnosis and prognosis of neurodegenerative diseases, such as a Tauopathy or Alzheimer's disease, are described. Compositions and methods for the treatment of neurodegenerative diseases are also described.



traducir


 

METHOD FOR ASSISTING DIAGNOSIS OF ALZHEIMER'S DISEASE USING URINE BIOMARKER

NºPublicación: WO2018030252A1 15/02/2018

Solicitante:
OTSUKA PHARMA CO LTD [JP]

Resumen de: WO2018030252A1

[Problem] To provide a method for assisting diagnosis of Alzheimer's disease (AD), a detection reagent and a diagnostic kit for use in the method, and a diagnostic system. [Solution] Provided is a method for assisting diagnosis of AD, the method including a step for measuring the amount of a urine biomarker in a urine sample originating from urine collected from a subject, and a step for determining whether the subject is affected by AD or has a high risk of AD onset on the basis of the measured amount of the urine biomarker, the urine biomarker being at least one type of urine protein selected from the group consisting of ApoA-I, ApoA-II, ApoA-IV, ApoB-100, ApoB-48, ApoC-I, ApoC-II, ApoC-III, ApoD, ApoE, IFITM1, IFITM2, IFITM3, NPC1, NPC2, NPC1L1, and MT.



traducir


 

METHODS FOR THE IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF NEUROLOGICAL DISORDERS AND DISEASES

NºPublicación: US2018038875A1 08/02/2018

Solicitante:
UNIV JOHNS HOPKINS [US]
UNIV WAKE FOREST [US]

Resumen de: US2018038875A1

Described herein are methods of identifying a mammal having a neurological disease or disorder, such as AD or MCI, or at risk for developing a neurological disease or disorder, such as AD or MCI. Provided herein are also methods of monitoring the progression of a neurological disease or disorder in a patient or monitoring the effectiveness of therapeutic agent or treatment of a patient having a neurological disease or disorder.



traducir


 

ANTIBODIES TO TAU

NºPublicación: US2018037641A1 08/02/2018

Solicitante:
UNIV WASHINGTON [US]

Resumen de: US2018037641A1

This invention relates to antibodies to tau and methods of use thereof.



traducir


 

Anti-pyroglutamated amyloid beta humanized antibodies

NºPublicación: AU2016293104A1 08/02/2018

Solicitante:
PROBIODRUG AG

Resumen de: AU2016293104A1

The invention relates to humanized antibodies that bind to an epitope at the N-terminus of pyroglutamated amyloid beta (Αβ N3pE) peptide and to preventive and therapeutic treatment of diseases and conditions that are related to accumulation and deposition of amyloid peptides, such as amyloidosis, a group of disorders and abnormalities associated with pyroglutamated amyloid peptide, like Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy and other related aspects. More specifically, it pertains to the use of humanized monoclonal antibodies to bind pyroglutamated amyloid beta peptide in plasma, brain, and cerebrospinal fluid to prevent accumulation or to reverse deposition of Αβ N3pE within the brain and in various tissues in the periphery, and to alleviate amyloidosis. The present invention further pertains to diagnostic assays for the diagnosis of amyloidosis using the humanized antibodies of the invention.



traducir


 

METHOD FOR DETECTING AGGREGATE FORM OF AGGREGATE-FORMING POLYPEPTIDE

NºPublicación: JP2018503807A 08/02/2018

Resumen de: WO2016088999A1

The present invention relates to a method for detecting an aggregate form of an aggregate-forming polypeptide in a biosample, comprising the steps of: (a) spiking, in a biosample to be analyzed, (i) a monomeric or multimeric form of an aggregate-forming polypeptide, (ii) a hydrophobic deleted derivative of the aggregate-forming polypeptide, or (iii) a monomeric or multimeric form of the aggregate-forming polypeptide and a hydrophobic deleted derivative of the aggregate-forming polypeptide; (b) additionally forming the aggregate form of the aggregate-forming polypeptide by incubating the product of step (a); (c) making the product of step (b) come into contact with a binder-label in which a signal-generating label is coupled to a binder binding to the aggregate form of the aggregate-forming polypeptide; and (d) detecting a signal to be generated from the binder-label bound to the aggregate form of the aggregate-forming polypeptide.



traducir


 

PERIPHERAL DIAGNOSTIC METHODS FOR SCREENING ALZHEIMER'S DISEASE USING BETA AMYLOID AND INTERCELLULAR COMMUNICATION

NºPublicación: EP3279638A1 07/02/2018

Solicitante:
ALKON DANIEL L [US]
CHIRILA FLORIN V [US]
KHAN TAPAN KUMAR [US]

Resumen de: EP3279638A1

The present disclosure relates to a peripheral diagnostic method for screening Alzheimer's disease in patients based on quantitatively measured complexity of skin-sampled fibroblast networks.



traducir


 

DIAGNOSTIC TOOLS FOR ALZHEIMER'S DISEASE

NºPublicación: CN107667293A 06/02/2018

Resumen de: WO2016124574A1

The present invention relates to methods of detecting Alzheimer's disease using novel biomarkers or sets thereof. The novel biomarkers can be measured in biological body fluids or easily available extracts of biopsies.



traducir


 

POLYMERS CONTAINING MULTIVALENT AMYLOID-BETA-BINDING D-PEPTIDES AND THEIR USE

NºPublicación: CN107652356A 02/02/2018

Resumen de: WO2013150127A2

The invention relates to novel multivalent amyloid-beta-binding polymeric substances consisting of a plurality of substances joined together which per se already have amyloid-beta-binding properties, and the use of these substances, called "polymers" hereinbelow, especially in medicine.



traducir


 

SALIVARY ABETA42 LEVELS AS PROGNOSTIC INDICATORS FOR ALZHEIMER'S DISEASE

NºPublicación: WO2018018138A1 01/02/2018

Solicitante:
AURIN BIOTECH INC [CA]

Resumen de: WO2018018138A1

Methods and kits for accurate determination of salivary levels of Abeta42 are provided. A method of analysing a saliva sample includes the steps of obtaining the saliva sample from a subject; stabilizing the saliva sample; measuring the level of Abeta42 present in the stabilized saliva sample by contacting the stabilized saliva sample with an antibody capable of binding to Abeta42; comparing the determined level of the Abeta42 present in the stabilized saliva with that of a control level of Abeta42 derived from a saliva sample of an unaffected control group sample; and displaying the comparison of the determined level and the control level, wherein the determined level relative being greater than the control level is indicative of Alzheimer's disease in the subject or the subject being at risk of developing Alzheimer's disease.



traducir


 

OCULAR DETECTION OF AMYLOID PROTEINS

NºPublicación: US2018028691A1 01/02/2018

Solicitante:
SYSTEM OF SYSTEMS ANALYTICS INC [US]

Resumen de: US2018028691A1

Described are methods for the detection, in the eye of an individual, of protein aggregates or other misfolded proteins associated with disease using peptide or peptide mimic probes that preferentially associate with the protein aggregates or misfolded proteins, which can be accomplished non-invasively.



traducir


 

THIOFLAVIN DERIVATIVES FOR USE IN ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION

NºPublicación: US2018028694A1 01/02/2018

Solicitante:
UNIV OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION [US]

Resumen de: US2018028694A1

This invention relates to novel thioflavin derivatives, methods of using the derivatives in, for example, in vivo imaging of patients having neuritic plaques, pharmaceutical compositions comprising the thioflavin derivatives and method of synthesizing the compounds. The compounds find particular use in the diagnosis and treatment of patients having diseases where accumulation of neuritic plaques are prevalent. The disease states or maladies include but are not limited to Alzheimer's disease, familial Alzheimer's disease, Down's Syndrome and homozygotes for the apolipoprotein E4 allele.



traducir


 

METHODS OF DIAGNOSING AND TREATING ALZHEIMER'S DISEASE WITH S-EQUOL

NºPublicación: WO2018022604A2 01/02/2018

Solicitante:
AUSIO PHARMACEUTICALS LLC [US]

Resumen de: WO2018022604A2

The present invention provides a method for diagnosing or determining the risk of developing Alzheimer's disease and for treating Alzheimer's disease with S-equol. An aspect of the present invention includes the use of a direct mitochondrial target engagement biomarker to diagnose or assess the risk of developing Alzheimer's disease. Another aspect of the present invention includes the use of a pharmaceutically effective amount of S-equol to treat or prevent Alzheimer's disease in a subject diagnosed with or determined to be at risk of developing Alzheimer's disease.



traducir


 

Detecting Dementia and Alzheimer's Disease Associated Biomarkers Stabilized on Solid Support Materials

NºPublicación: US2018031575A1 01/02/2018

Solicitante:
GE HEALTHCARE UK LTD [GB]

Resumen de: US2018031575A1

Embodiments of the invention provides a method for detecting one or more biomarkers derived from a body fluid, comprising performing one or more assays for the biomarkers from a sample of the body fluid, whereby the sample is previously preserved on a solid support; wherein a change in the biomarkers provides an indication of a biological event in the brain. The invention also provides related methods for identifying a person as being at risk of dementia or Alzheimer's disease, monitoring a person for the onset or progression of dementia or Alzheimer's disease, evaluating the effectiveness of a potential pharmaceutical agent.



traducir


 

DEVICES, SOLUTIONS AND METHODS FOR SAMPLE COLLECTION RELATED APPLICATIONS, ANALYSIS AND DIAGNOSIS

NºPublicación: US2018031543A1 01/02/2018

Solicitante:
ABOGEN INC [US]

Resumen de: US2018031543A1

A solution is described for preserving cells and/or extra-cellular components in naturally expressed bodily fluids (e.g. saliva, sputum, urine) for further downstream analysis and/or for diagnosis of a medical condition. The solution may be hypertonic with respect to blood. Techniques are described for enriching cells from a sample of a naturally expressed bodily fluid, and/or for analysis, e.g. to diagnose medical conditions such as cancer, obesity, infections, autism, Alzheimer disease, hetotological disorders, cardiovascular disease or disorders, diabetes, vulnerable plack, LTBI, HIV infection, COPD, ACQS.



traducir


 

SYSTEM AND METHOD FOR EARLY DETECTION OF ALZHEIMERS BY DETECTING AMYLOID-BETA USING ORBITAL ANGULAR MOMENTUM

NºPublicación: US2018031538A1 01/02/2018

Solicitante:
NXGEN PARTNERS IP LLC [US]

Resumen de: US2018031538A1

An apparatus for measuring a concentration of amyloid-beta within a chiral solution includes signal generation circuitry for generating a first signal having an applied first orbital angular momentum signature and applying the first signal to the chiral solution. A detector for receiving the first signal after the first signal passes through the chiral solution and determining the concentration of amyloid-beta within the chiral solution based on a detected second orbital angular momentum signature received from the chiral solution that comprises an amplitude measurement and a phase measurement.



traducir


 

METHODS OF DIAGNOSING AND TREATING ALZHEIMER'S DISEASE WITH S-EQUOL

NºPublicación: US2018028491A1 01/02/2018

Solicitante:
AUSIO PHARMACEUTICALS LLC [US]

Resumen de: US2018028491A1

The present invention provides a method for diagnosing or determining the risk of developing Alzheimer's disease and for treating Alzheimer's disease with S-equol. An aspect of the present invention includes the use of a direct mitochondrial target engagement biomarker to diagnose or assess the risk of developing Alzheimer's disease. Another aspect of the present invention includes the use of a pharmaceutically effective amount of S-equol to treat or prevent Alzheimer's disease in a subject diagnosed with or determined to be at risk of developing Alzheimer's disease.



traducir


 

A NOVEL NERVOUS SYSTEM-SPECIFIC TRANSMEMBRANE PROTEASOME COMPLEX THAT MODULATES NEURONAL SIGNALING THROUGH EXTRACELLULAR SIGNALING VIA BRAIN ACTIVITY PEPTIDES

NºPublicación: US2018031576A1 01/02/2018

Solicitante:
UNIV JOHNS HOPKINS [US]

Resumen de: US2018031576A1

The inventors surprisingly found that neural stimulation caused the synthesis and degradation of proteins into peptides which were then secreted into the cell media within minutes of stimulation by a novel neural-specific and membrane bound proteasome (neuronal membrane proteasome or NMP) that is transmembrane in nature. These secreted, activity-induced, proteasomal peptides (SNAPPs) range in size from about 500 Daltons to about 3000 Daltons. Surprisingly none of the peptides appear to be those previously known to have any neuronal function. Moreover, these SNAPPs have stimulatory activity and are heretofore a new class of signaling molecules. Moreover, the NMP appears to play a highly significant role in aspects of neuronal signaling known to be critical for neuronal function. The inventors have gone on to develop all tools to study this novel mechanisms including protocols and practice for generation and purification of SNAPPs as well as a new and specific inhibitor of the NMP allowing for selective control of this process in the nervous system. The present invention provides methods of making and using these SNAPPs for both laboratory and clinical purposes, the screening for molecules which modulate NMP function in vivo and in vitro, and methods for diagnosis of NMP related diseases.



traducir


 

METHODS OF TREATING OR PREVENTING AMYLOID RELATED IMAGING ABNORMALITIES ASSOCIATED WITH ALZHEIMER'S DISEASE TREATMENT

NºPublicación: WO2018023036A1 01/02/2018

Solicitante:
BIOGEN CHESAPEAKE LLC [US]

Resumen de: WO2018023036A1

A method of treating or preventing amyloid related imaging abnormalities (ARIA) in patients receiving one or more course of medical treatment for Alzheimer's Disease includes administrating a SUR1-TRPM4 channel inhibitor, such as glyburide, in an amount effective to prevent the formation or reduce the size of one or more ARIAs in the brain.



traducir


 

METHODS FOR APOLIPOPROTEIN DETECTION

NºPublicación: EP3274725A2 31/01/2018

Solicitante:
BIOCROSS S L [ES]
INST DE SALUD CARLOS III [ES]
CENTRO DE INVESTIGAC\u00CDON BIOM\u00C9DICA EN RED DE ENFERMEDADES NEURODEGENERATIVAS CIBERNED [ES]

Resumen de: EP3163303A1

The present invention relates to methods for the detection and quantification of apolipoproteins and isoforms thereof in a sample, as well as to predictive methods of the probability of neurodegenerative or cardiovascular disease development based on apolipoprotein levels as determined by the detection methods of the invention.



traducir


 

Antibody

NºPublicación: EP3274371A1 31/01/2018

Solicitante:
NEURO-BIO LTD [GB]

Resumen de: GB2541477A

Antibodies for use in the diagnosis and treatment of neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease. The antibody specifically binds to the T14 peptide or a variant or fragment thereof of acetylcholinesterase (AChE). Also claimed is the use of the T14 peptide as a biomarker for detecting or diagnosing a neurodegenerative disorder and the ex vivo use of a colourimetrically- or fluorescently-labelled T14 peptide for identifying an agent which inhibits T14 peptide synthesis or activity.



traducir


 

PROTEIN-BASED THERAPY AND DIAGNOSIS OF TAU-MEDIATED PATHOLOGY IN ALZHEIMER'S DISEASE FIELD

NºPublicación: EP3275461A1 31/01/2018

Solicitante:
AXON NEUROSCIENCE SE [CY]

Resumen de: EP3275461A1

The invention provides unique therapeutic and diagnostic antibodies, as well as their fragments, portions, derivatives, and variants thereof, that bind regions of the tau protein that contribute to the initiation and propagation of pathological tau-tau interactions, as well as methods of making them. The invention also relates to methods of using those antibodies for diagnostics, prevention, and treatment of Alzheimer's disease and related tauopathies. The present invention also provides a method for a prophylactic and therapeutic treatment of Alzheimer's disease and other neurodegenerative tauopathies. This method entails the injection of antibodies and/or peptide vaccines that elicits an immune response directed to pathological tau proteins and tau deposits in the brains of patients. Suitable vaccines represent a tau peptide carrying one or more of the tau therapeutic epitopes provided herein.



traducir


 

Raman, infrared, or raman-infrared analysis of peripheral blood plasma protein structure and its relation to cognitive development in alzheimer’s disease

NºPublicación: NZ706107A 26/01/2018

Solicitante:
CONSEJO SUPERIOR DE INVESTIG CIENT\u00CDFICAS C S I C
FUNDACI\u00D3N INVESTIGACI\u00D3N BIOM\u00C9DICA HOSPITAL UNIV 12 DE OCTUBRE
INST DE SALUD CARLOS III
FUNDACI\u00D3N CIEN
UNIV MADRID COMPLUTENSE

Resumen de: NZ706107A

The present invention relates to a Raman spectroscopy method for determining protein structure associated with global cognitive deterioration in Alzheimer’s disease from the Raman spectroscopic analysis of a human blood sample, preferably of a human blood plasma sample, comprising obtaining at least one spectral value of at least one of the Raman spectrum regions comprised between 1600-1700 cm-1, between 910-980 cm-1, between 730-760 cm-1 and/or between 390-450 cm-1, and where said spectral value allows obtaining an indication of the presence or absence of protein structure associated with a condition of Alzheimer’s disease. The present invention also relates to a method for the infrared spectroscopic analysis of a blood sample, by means of additionally obtaining at least one spectral value of at least one of the infrared spectrum regions comprised between 1600 and 1700 cm-1, and/or between 1000 and 1150 cm-1 and/or between 1140 and 1190 cm-1 Optionally, the Raman spectroscopy method further comprises the infrared spectroscopic analysis of the same blood sample. The invention also relates to a diagnostic method for diagnosing Alzheimer’s disease comprising measuring a Raman spectrum and/or an infrared spectrum of a plasma sample.



traducir


 

BIOMARKER OF DEMENTIA WITH LEWY BODIES

NºPublicación: US2018024150A1 25/01/2018

Solicitante:
UNIV NIIGATA [JP]
EISAI R&D MAN CO LTD [JP]

Resumen de: US2018024150A1

Cholesterol and desmosterol levels, and the ratio of these levels can be used as a blood biomarker for Alzheimer's disease, frontotemporal lobar degeneration, or dementia with Lewy bodies.



traducir


 

ALZHEIMER'S DISEASE-SPECIFIC ALTERATIONS OF THE ERK1/ERK2 PHOSPHORYLATION RATIO-ALZHEIMER'S DISEASE-SPECIFIC MOLECULAR BIOMARKERS (ADSMB)

Nº publicación: US2018024146A1 25/01/2018

Solicitante:
BLANCHETTE ROCKEFELLER NEUROSCIENCES INST [US]

Resumen de: US2018024146A1

The present invention relates to methods of diagnosing Alzheimer's Disease as well as to methods of confirming the presence or absence of Alzheimer's Disease in a subject. The present invention is also directed to methods of identifying a lead compound useful for the treatment of Alzheimer's Disease by contacting non-Alzheimer's cells with an amyloid beta peptide, stimulating the cells with a protein kinase C activator, contacting the cells with a test compound, and determining the value of an Alzheimer's Disease-specific molecular biomarker. The present invention is also directed to methods of diagnosing Alzheimer's Disease in a subject by detecting alterations in the ratio of specific phosphorylated MAP kinase proteins in cells after stimulation with a protein kinase C activator. The Alzheimer's Disease-specific molecular biomarkers disclosed herein are useful for the diagnosis of Alzheimer's Disease, monitoring the progression of Alzheimer's Disease in a subject and in screening methods for the identification of compounds for treating or preventing Alzheimer's Disease. The invention is also directed to kits containing reagents for the detection and diagnosis of the presence or absence of Alzheimer's Disease using the. Alzheimer's Disease-specific molecular biomarkers disclosed herein.


traducir



 

Página1 de 3 nextPage Mostrar por página

Volver